Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
Oct 24, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
T2D is associated with micro- and macrovascular complications that significantly increase the burden of this disease. Diabetic nephropathy is one such complication associated with increased mortality and reduced quality of life in diabetes patients. Trials such as the CREDENCE and EMPA-REG OUTCOMES trials have shown the benefit of SGLT2is in preventing kidney disease progression and reducing outcomes. There is a lack of evidence that confirms the effectiveness of antihyperglycemic agents in the real world setting or compares current agents' effectiveness in reducing renal effects.
A new study aimed to provide real-world evidence to compare older add-on antihyperglycemic agents' effectiveness versus newer agents in reducing renal outcomes....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.